DMFT/DMFS index (dental caries experience) · Children aged 6 years and older (healthy except for dental caries)
In children aged 6 years and older, OHPPs showed no significant effect on DMFT/S (OR 0.29, 95% CI 0.08 to 1.01; ungraded).
1 finding from 1 review
Incremental cost‐effectiveness · Children with dental caries
OHPPs were associated with a lower program cost per DMFT/S in about 97 of 100 programs (OR 0.03, 95% CI 0.01 to 0.11; ungraded, very high heterogeneity I2=99%).
1 finding from 1 review
OR 0.03 [0.01, 0.11]
8 studies
GRADE not reported
Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
The review found no eligible studies for this question.
1 finding from 1 review
Side effects or other adverse events · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).
1 finding from 1 review
DMFT/DMFS index (dental caries experience) · Children younger than 6 years (healthy except for dental caries)
In children younger than 6 years, OHPPs were associated with lower odds of DMFT/S (OR 0.14, 95% CI 0.05 to 0.39; ungraded).
1 finding from 1 review
Major bleeding, requiring transfusion of packed red blood cells · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in major bleeding requiring transfusion of packed red blood cells compared with standard care (usual local haemostatic measures: gelatin sponge and…; GRADE not reported.
1 finding from 1 review
Number of participants with postoperative bleedings requiring intervention · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in number of participants with postoperative bleedings requiring… compared with standard care (usual local haemostatic measures: gelatin sponge and… (moderate certainty).
1 finding from 1 review
Caries increment, surface index D(M)FS · Children with high risk of dental decay
It is very uncertain whether slow-release fluoride device (fluoride glass beads) changes increase in DMFS at 2 years compared with baseline compared with placebo or usual care (control) (very low certainty).
1 finding from 1 review
Caries increment, tooth index D(M)FT · Children with high risk of dental decay
It is very uncertain whether slow-release fluoride device (fluoride glass beads) changes increase in DMFT at 2 years compared with baseline compared with placebo or usual care (control) (very low certainty).
1 finding from 1 review
Progression of caries lesion into enamel or dentine · Children with high risk of dental decay
The review found no eligible studies for this question.
1 finding from 1 review
No evidence found
0 studies
No studies found
Dental pain due to decay · Children with high risk of dental decay
The review found no eligible studies for this question.
1 finding from 1 review
No evidence found
0 studies
No studies found
Antifibrinolytic agents (tranexamic acid (TXA) or epsilon aminocaproic acid (EACA)) vs Placebo, no intervention, or usual care
Outcome not reported · People on continuous direct oral anticoagulant (DOAC) treatment undergoing oral or dental procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Retention of slow-release fluoride devices (devices staying intact) · Children with high risk of dental decay
1 finding from 1 review
ICU/HDU admission ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
Symptom score at 10 days. Measured on a 7‐point scale (0 to 6) ; lower score denotes fewer symptoms · acute asthma exacerbation
1 finding from 1 review
All adverse events · acute asthma exacerbation
Antibiotics showed no clear difference in all adverse events compared with placebo or usual care (low certainty).
1 finding from 1 review
Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
1 finding from 1 review
Mortality ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
Length of hospital stay · acute asthma exacerbation
1 finding from 1 review
Relapse ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review